MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) said its experimental ketamine-based drug outperformed currently available pain treatments in preclinical studies, building on months of research that show why the compound might succeed where other treatments have failed. The drug, known as Ketamir-2, demonstrated up to 112% more effective results than pregabalin (Lyrica) …

Incannex Healthcare Inc. (Nasdaq: IXHL) announced Tuesday it has secured a financing agreement with Arena Investors, LP for up to $60 million, in a bid to advance the company’s clinical-stage drug candidates. The deal includes up to $10 million in secured convertible notes and a $50 million equity line of …

The recent news that the Drug Enforcement Administration scheduled an administrative hearing for Dec. 2 to “consider differing expert opinions regarding rescheduling of cannabis to schedule III” put many cannabis companies on edge. “The cannabis equity market lurched violently downward on the news as it clearly pushed the issuance of …